Enlicitide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Enlicitide is the first PCSK9 cholesterol drug you can swallow. In 2,909 people it cut LDL cholesterol by 57 percent. Until now, drugs of this kind were all shots.
Evidence grade for Enlicitide: Strong. The rule: at least two finished studies in people, and at least 1,000 people who took it. The sum on this page: 3 completed trials, 2,909 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 2,909
- Human studies
- 3
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved 2026 for lowering LDL ("bad") cholesterol. Prescription only.
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Heart and circulation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Enlicitide is a daily pill that lowers LDL, the bad cholesterol. It is the first drug of its kind you can swallow. Until now, PCSK9 drugs were all shots. It was approved in the US in 2026 and needs a prescription.
What people take it for
- Lowering LDL cholesterol a lot.
- A pill instead of a shot for heart risk.
- Adding to a statin when LDL is still too high.
What studies in people showed
The main study had 2,909 adults with heart disease or at risk of it. They took the pill or a dummy pill for a year. LDL fell 57.1 percent on the pill. It rose 3.0 percent on the dummy. Other harmful blood fats fell too. A second study had 301 people already on a statin. LDL fell about 65 percent on enlicitide. It fell 37 percent on two older pills together, 28 percent on ezetimibe alone and 6 percent on bempedoic acid alone. Side effects looked alike across the groups. No study has yet shown fewer heart attacks. The maker paid for the studies.
What people report
Reports, not study results
The good
- In the studies on this page, LDL cholesterol fell by more than half.
The bad
- No study has shown fewer heart attacks or strokes yet. The studies measured cholesterol.
Where these come from: Both lines are from the studies on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Know your LDL. It is one of the blood work numbers I care about most. If yours is high, this is a real option to raise with your doctor.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Enlicitide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Cholesterol and blood fats2,909 people · 1 study
35 of the 36 indexed goals have no study of any kind behind Enlicitide
No study in people, animals or cells on this page reports a result for these. That does not prove Enlicitide does nothing for them. It does mean anything you have heard about Enlicitide and one of these did not come from a study cited here.
Show full evidence
What is Enlicitide?
Enlicitide is the first PCSK9 cholesterol drug you can swallow. In 2,909 people it cut LDL cholesterol by 57 percent. Until now, drugs of this kind were all shots.
PCSK9 drugs lower LDL, the bad cholesterol, a lot. Until 2026, all of them were shots. Enlicitide is a ring-shaped peptide built to survive the gut, so it can be taken as a daily pill. That is hard, because the gut normally destroys peptides. Even with a helper that boosts absorption, only about one percent gets into the body. That one percent is enough. In the CORALreef Lipids study, 2,909 adults with heart disease, or at risk of a first heart event, took enlicitide or a dummy pill. LDL fell 57.1 percent, while it rose 3.0 percent on the dummy. In a second study of 301 people already on a statin, LDL fell about 65 percent on enlicitide, against 37 percent on two older pills combined. It is worth knowing about even if you never take it. It proves a peptide pill can hit a target that used to need a needle.
How does Enlicitide work?
It grabs PCSK9 and stops it from reaching the LDL receptor. PCSK9 normally marks those receptors for destruction. With it blocked, the liver keeps more receptors to pull LDL out of the blood. The pill works because its ring shape resists gut enzymes, and it is taken with a helper that boosts absorption.
What have studies in people found about Enlicitide?
Large and recent. There is a large final-stage study against a dummy pill, published in a top journal, and an approval behind it.
- CORALreef Lipids: 2,909 people, 52 weeks, against a dummy pill. LDL fell 57.1 percent against a 3.0 percent rise, a gap of 55.8 points.
- Other harmful blood fats, non-HDL cholesterol, apolipoprotein B and lipoprotein(a), also improved.
- A separate final-stage study of 301 people on a statin compared it with the older cholesterol pills rather than a dummy pill. LDL fell about 65 percent on enlicitide, 37 percent on bempedoic acid plus ezetimibe, 28 percent on ezetimibe alone and 6 percent on bempedoic acid alone.
What this does not tell you: Every study so far measures cholesterol, not heart attacks. Across other drugs, lower LDL is strongly linked to fewer heart attacks. But a study of heart attacks and strokes for this drug has not reported. The maker paid for the studies, which is normal for a drug and worth saying.
The state of the research
Enlicitide matters to this site for more than cholesterol. The usual view is that peptides cannot be swallowed, because digestion destroys them. That is why almost every peptide on this site is a shot. Enlicitide breaks that rule at scale. It is a ring-shaped peptide of 1,722 daltons. Only about one percent gets absorbed, and that was still enough to cut LDL by 57 percent in nearly three thousand people.
That matters for the whole field. If a ring shape plus an absorption helper can get a peptide this size in by mouth, fewer targets will need a needle. Watch the idea more than this one drug.
The evidence, in charts
Fig. 1a · how many people
2,909people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| New England Journal of Medicine 2026 | 2,909 | 100% |
The whole total is one study of 2,909. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 3 sources here are studies in people.
- Study in people · done in people3100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Prescription
AU
Prescription
CA
Prescription
Approved in 1 of 4, by prescription in 3, not approved in 0. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Approximately 1,722 Da
- Half-life
- About 14 hoursMedium, 6 to 24 hours
- Chain length
- None on file
Half-life as stated on file: Effective half-life around 14 hours; terminal half-life considerably longer
No amino acid sequence is on file for Enlicitide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide
A PCSK9 drug you swallow works, and until now this kind of drug needed a shot. 2,909 people took enlicitide pills or a dummy pill for a year. Their LDL cholesterol fell by about 57 percent, while the dummy group drifted up 3 percent. Other harmful blood fats improved too. This study measured cholesterol, not heart attacks. Whether those falls turn into fewer heart attacks and strokes has not been shown. The maker paid for the study.
2,909 participants randomised 2:1 to enlicitide 20 mg or placebo for 52 weeks. LDL cholesterol fell 57.1 percent at week 24 against a 3.0 percent rise on placebo, an adjusted between-group difference of 55.8 percentage points (p < 0.001). Non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also improved. Funded by the manufacturer.
- Study in people2026Oral PCSK9 inhibitor enlicitide versus oral nonstatin therapies: a phase 3 randomized clinical trial
Put up against the other cholesterol pills, LDL fell furthest on enlicitide. 301 adults already taking a statin took enlicitide, bempedoic acid, ezetimibe, or the last two together, for eight weeks. LDL cholesterol fell about 65 percent on enlicitide, 37 percent on the two older drugs combined, 28 percent on ezetimibe alone and 6 percent on bempedoic acid alone. Side effects looked similar across all four. Eight weeks measures cholesterol, not heart attacks, and the maker paid for it.
Randomised comparison of enlicitide against the existing oral nonstatin options rather than against placebo alone.
- Study in people2026CORALreef Lipids trial record
This is the registry entry for the main trial, not a report of what it found. It sets out the plan: who could join, what would be given, and what would be measured. Records like this exist so that a trial cannot quietly change what it was testing once the results come in. No results are posted here. The published paper carries them.
The registered protocol for the pivotal placebo-controlled trial.
Where to buy Enlicitide
Enlicitide is an approved medicine. The approved product comes from a pharmacy, with a prescription. The vials below are sold “for research” and are not the approved drug.
No seller we track lists Enlicitide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Enlicitide been tested in people?
Yes. 2,909 people given it across 3 completed trials cited here, 0 of which found nothing. Enlicitide is the first PCSK9 cholesterol drug you can swallow. In 2,909 people it cut LDL cholesterol by 57 percent. Until now, drugs of this kind were all shots.
What is the Enlicitide dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA approved 2026 for lowering LDL ("bad") cholesterol. Prescription only.
Is Enlicitide FDA-approved?
FDA approved 2026 for lowering LDL ("bad") cholesterol. Prescription only.
Is this the first oral PCSK9 inhibitor?
Yes. Every PCSK9 drug approved before it is a shot. Enlicitide is a ring-shaped peptide built to survive digestion and be taken as a daily pill.
How much does it lower LDL?
By 57.1 percent at 24 weeks in the main study of 2,909 people, against a 3.0 percent rise on a dummy pill. That is in the same range as the shots in this drug class.
Does it prevent heart attacks?
That has not been shown for this drug yet. The studies measured cholesterol. Across other drugs, lower LDL is strongly linked to fewer heart attacks and strokes. But the heart attack study for enlicitide has not reported.
Why does one percent bioavailability still work?
Because the target is in the liver, which is the first organ the drug reaches after it is absorbed. The dose is also set high enough to make up for the loss. It is an engineering fix, not a biological one.